Genodermatoses 2003-2004

Current Opinion in Pediatrics

Volumn 16, Issue 6, 2004, Pages 678-688

  Schnur, Rhonda E ^a  

^a UMDNJ Robert Wood Johnson Medical School at Camden   (United States)

Author keywords

Connexin genes; Ectodermal dysplasia; Genodermatoses; Incontinentia pigmenti; NEMO; Neurofibromatosis; NF B; p63; Revertant gene mosaicism; Signal transduction; Tuberous sclerosis

Indexed keywords

GAP JUNCTION PROTEIN; HAMARTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NEUROFIBROMIN; PROTEIN P63; TUBERIN;

AUTOANALYSIS; BENIGN TUMOR; CLINICAL GENETICS; DIFFERENTIAL DIAGNOSIS; ECTODERMAL DYSPLASIA; GENE MUTATION; GENE THERAPY; GENETIC ASSOCIATION; GENETIC COUNSELING; GENODERMATOSIS; GENOTYPE PHENOTYPE CORRELATION; GLIOMA; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR GENETICS; MOSAICISM; MULTIGENE FAMILY; NEUROFIBROMATOSIS; PEDIATRICS; PHAKOMATOSIS; PRACTICE GUIDELINE; PRECANCER; PRIORITY JOURNAL; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS; VISUAL SYSTEM;

ADOLESCENT; CHILD; ECTODERMAL DYSPLASIA; FEMALE; HUMANS; INCONTINENTIA PIGMENTI; MALE; NEUROFIBROMATOSIS 1; TUBEROUS SCLEROSIS;

EID: 9244249844     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000145727.95637.d6     Document Type: Review

References (75)

1. Irvine AD, McLean WH: The molecular genetics of the genodermatoses: progress to date and future directions. Br J Dermatol 2003, 148:1-13. This is a relatively recent, very comprehensive overview of the field, which categorizes all the genodermatoses, reviews basic genetic concepts and inheritance patterns, and discusses the future of the field.
2. Arun D, Gutmann DH: Recent advances in neurofibromatosis type 1. Curr Opin Neurol 2004, 17:101-105. This is a comprehensive overview of a large subject from both basic science and clinical perspectives.
3. Tong J, Hanna F, Zhu Y, et al.: Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat Neurosci 2003, 5:95-96.
4. Dasgupta B, Dugan LL, Gutmann DH: The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci 2003, 23:8949-8954.
5. Frahm S, Mautner VR, Brems H, et al.: Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients. Neurobiol Dis 2004, 16:85-91. This article notes specific characteristics that help to distinguish malignant from benign tumors in NF1.
6. Holtkamp N, Mautner VF, Friedrich RE, et al.: Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. Acta Neuropathol (Berl) 2004, 107:159-168. The profile of expressed genes in malignant tumors is studied by use of suppression-subtractive hybridization. Identification of differentially expressed genes is potentially helpful in diagnosis, understanding the biology of tumor formation, and the development of directed therapeutic approaches.
7. Lévy P, Vidaud D, Leroy K, et al.: Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis. Clin Cancer Res 2004, 10:3763-3771. This paper reports that reverse-transcription polymerase chain reaction is potentially useful for detecting genetic markers that confer increased risk for malignant transformation within preexisting benign plexiform neurofibromas.
8. Kluwe L, Friedrich RE, Peiper M, et al.: Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors. Hum Mutat 2003, 22:420. This report concludes that the nature of the underlying constitutional NF1 mutation may affect the risk of malignancy, which may be particularly high in patients with gene deletions.
9. Kluwe L, Siebert R, Gesk S, et al.: Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene. Hum Mutat 2004, 23:111-116.
10. Messiaen LM, Callens T, Mortier G, et al.: Exhaustive mutation analysis of the NF1 gene allows identification of 95[ref] of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 2000, 15:541-555.
11. Mattocks C, Baralle D, Tarpey P, et al.: Automated comparative sequence analysis identifies mutations in 89[ref] of NF1 patients and confirms a mutation cluster in exons 11-17 distinct from the GAP related domain. J Med Genet 2004, 41:e48. The authors describe the results of a promising new technique that may significantly affect the way mutation screening is performed for NF1.
12. Listernick R, Charrow J: Knowledge without truth: screening for complications of neurofibromatosis type 1 in childhood. Am J Med Genet 2004, 127A:221-223. This article reviews screening techniques for optic pathway tumors and other malignant complications of NF1, acknowledging the numerous controversies yet to be resolved in the management of this disease.
13. Thiagalingam S, Flaherty M, Billson F, et al.: Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 2004, 111:568-577. This is a very thorough clinical long-term study that raises additional questions about the management of optic pathway tumors in NF1.
14. Listernick R, Louis DN, Packer RJ, et al.: Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997, 41:143-149.
15. King A, Listernick R, Charrow J, et al.: Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet 2003, 122A:95-99.
16. Blazo MA, Lewis RA, Chintagumpala MM, et al.: Outcomes of systematic screening for optic pathway tumors in children with neurofibromatosis type 1. Am J Med Genet 2004, 127A:224-229. The article presents evidence that early routine neuroimaging for optic pathway tumors, even in patients without signs or symptoms, should be reconsidered. Patients may also have relatively late complications of these tumors.
17. Manning BD, Cantley LC: Rheb fills a GAP between TSC and TOR. Trends Biochem Sci 2003, 28:573-575. This is an excellent review of recent breakthroughs in the molecular biologic pathway that underlies tuberous sclerosis. The localization of the tuberin-hamartin protein complex within a cascade of other proteins that regulate cellular proliferation may lead to directed pharmacologic treatment of tuberous sclerosis complex.
18. Pan D, Dong J, Zhang Y, et al.: Tuberous sclerosis complex: from Drosophila to human disease. Trends Cell Biol 2004, 14:78-85. This is a comprehensive overview of the interacting signaling pathways of the TSC system.
19. Castro AR, Rebhun JF, Clark GJ, et al.: Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 Kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem 2003, 278:32493-32496. This is a key paper that links loss of TSC2 GAP activity to clinical disease and explores the effects of deficient TSC2 on other signaling molecules, including Rheb-GTP and mTOR.
20. Tee AR, Manning BD, Aroux PP, et al.: Tuberous sclerosis complex gene products, tuberin and hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 2003, 13:1259-1268. This article links clinical mutations within the GAP domain of tuberin and defects in GAP activity toward Rheb. It also confirms the placement of Rheb within the signaling pathway in a position immediately downstream of TSC1/TSC2 and upstream of TOR.
21. Li Y, Corradetti MN, Inoki K, et al.: TSC2: filling the GAP in the mTOR signaling pathway. Trends Biol Sc 2004, 29:32-38. The authors review evidence that TSC2 (of the two components of the TSC1/TSC2 complex) is the more precise site of the GAP regulatory activity for Rheb.
22. Sulis ML, Parsons R: PTEN: from pathology to biology. Trends Cell Biol 2003, 13:478-483. This good review article connects PTEN and the TSC genes within the signaling pathway.
23. Brugarolas JB, Vazques F, Reddy A, et al.: TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 2003, 4:147-158. This is an excellent review of the influence of TSC2 on angiogenesis, a contributing factor in tumorigenesis. Possible pharmacologic interventions to treat TSC are suggested.
24. Dabora SL, Jozwiak S, Franz DN, et al.: Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001, 68:64-80.
25. Roberts PS, Dabora S, Thiele EA, et al.: Somatic mosaicism is rare in unaffected parents of patients with sporadic tuberous sclerosis. J Med Genet 2004, 41:e69.
26. Verhoef S, Bakker L, Tempelaars AM, et al.: High rate of mosaicism in tuberous sclerosis complex. Am J Hum Genet 1999, 64:1632-1637.
27. Lewis JC, Thomas HV, Murphy KC, et al.: Genotype and psychological phenotype in tuberous sclerosis. J Med Genet 2004, 41:203-207. This is a phenotypic study of a moderate-size group of patients (92) with defined mutations, although the number (22) of subjects with TSC1 mutations studied was relatively low. The severity of symptoms was assessed and correlated with the mutated locus (TSC1 vs TSC2) in each subject. Overall, TSC2 mutations are associated with a less favorable prognosis for neurocognitive function compared with TSC1 mutations.
28. Roberts PS, Ramesh V, Dabora S, et al.: A 34 bp deletion within TSC2 is a rare polymorphism, not a pathogenic mutation. Ann Hum Genet 2003, 67:495-503. The report describes a rare deletion polymorphism that may modify the TSC phenotype when a second pathologic, but possibly mild or mosaic, mutation is present.
29. Lamartine J: Towards a new classification of ectodermal dysplasias. Clin Exp Dermatol 2003, 28:351-355. A new classification of ED is proposed based on the functions of the underlying molecular causes.
30. van Bokhoven H, Brunner HG: Splitting p63. Am J Hum Genet 2002, 71:1-13.
31. Brunner HG, Hamel BCJ, Van Bokhoven H: The p63 gene in EEC and other syndromes. J Med Genet 2002, 39:377-381.
32. Westfall MD, Pietenpol JA: p63: Molecular complexity in development and cancer. Carcinogenesis 2004, 25:857-864. This is an excellent review of p63 biology, including its function as a transcription factor and regulator of the cell cycle. The roles of p63 in epithelial development and in tumorigenesis are also summarized.
33. Kantaputra PN, Hamada T, Kumchai T, et al.: Heterozygous mutation in the SAM domain of p63 underlies Rapp-Hodgkin ectodermal dysplasia. J Dent Res 2003, 82:433-437.
34. Dianzani I, Garelli E, Gustavsson P, et al.: Rapp-Hodgkin and AEC syndromes due to a new frameshift mutation in the TP63 gene. J Med Genet 2003, 40:e133.
35. Bougeard G, Hadj-Rabia S, Faivre L, et al.: The Rapp-Hodgkin syndrome results from mutations of the TP63 gene. Eur J Hum Genet 2003, 11:700-704.
36. Bertola DR, Kim CA, Albano LMJ, et al.: Molecular evidence that AEC syndrome and Rapp-Hodgkin syndrome are variable expression of a single genetic disorder. Clin Genet 2004, 66:79-80. This paper is important in establishing that Rapp-Hodgkin and AEC syndromes are molecularly indistinguishable disorders with a variable clinical spectrum.
37. Gorlin RJ, Cohen MM, Hennekam RCM: Syndromes of the Head and Neck, edn. 4. Oxford: Oxford University Press; 2001:883-886.
38. Akahoshi K, Sakazume S, Kosaki K, et al.: EEC syndrome type 3 with a heterozygous germline mutation in the p63 gene and B-cell lymphoma. Am J Med Genet 2003, 120A:370-373. This paper and two previous case reports suggest a risk of lymphoma in p63-related disorders.
39. Gershoni-Baruch R, Goldscher D, Hochberg Z: Ectrodactyly-ectodermal dysplasia-clefting syndrome and hypothalamo-pituitary insufficiency. Am J Med Genet 1997, 68:168-172.
40. Ogutcen-Toller M, Gulen O, Okten G, et al.: Non-Hodgkin's lymphoma in a patient with ectrodactyly ectodermal dysplasia-clefting syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000, 90:124-125.
41. Richard G: Connexin gene pathology. Clin Exp Dermatol 2003, 28:397-409. This is an excellent review of both the basic science and the clinical implications of connexin gene alterations.
42. Brandner JM, Houdek P, Husing B, et al.: Connexins 26, 30, and 43: differences among spontaneous, chronic, and accelerated human wound healing. J Invest Dermatol 2004, 122:1310-1320.
43. Jan AY, Amin S, Ratajczak P, et al.: Genetic heterogeneity of KID syndrome: identification of a Cx30 gene (GJB6) mutation in a patient with KID syndrome and congenital atrichia. J Invest Dermatol 2004, 122:1108-1113. This report links the keratitis-ichthyosis-deafness syndrome to a second connexin gene. It is also a good review of several genetic diseases associated with connexin mutations.
44. Richard G, Smith LE, Bailey RA, et al.: Mutations in the human connexin gene GJB3 cause erythrokeratodermia variabilis. Nat Genet 1998, 20:366-369.
45. Macari F, Landau M, Cousin P, et al.: Mutation in the gene for connexin 30.3 in a family with erythrokeratodermia variabilis. Am J Hum Genet 2000, 67:1296-1301.
46. Richard G, Brown N, Rouan F, et al.: Genetic heterogeneity in erythrokeratodermia variabilis: novel mutations in the connexin gene GJB4 (Cx30.3) and genotype-phenotype correlations. J Invest Dermatol 2003, 120:601-609.
47. Richard G, White TW, Smith LE, et al.: Functional defects of Cx26 resulting from a heterozygous missense mutation in a family with dominant deaf-mutism and palmoplantar keratoderma. Hum Genet 1998, 103:393-399.
48. Maestrini E, Korge BP, Ocana-Sierra J, et al.: A missense mutation in connexin 26, D66H, causes mutilating keratoderma with sensorineural deafness (Vohwinkel's syndrome) in three unrelated families. Hum Mol Genet 1999, 8:1237-1243.
49. Schmuth M, Fluhr JW, Crumrine DC, et al.: Structural and functional consequences of loricrin mutations in human loricrin keratodermal (Vonwinkel syndrome with ichthyosis). J Invest Dermatol 2004, 122:909-922.
50. Bakirtzis G, Choudhry R, Aasen T, et al.: Targeted epidermal expression of mutant Connexin 26(D66H) mimics true Vohwinkel syndrome and provides a model for the pathogenesis of dominant connexin disorders. Hum Mol Genet 2003, 12:1737-1744. This mouse model is a prototype of models for other connexin-related disorders in which a specific dominant negative mutation is introduced, is expressed, and results in a phenotype that resembles the human disease.
51. Richard G, Rouan F, Willoughby CE, et al.: Missense mutations in GJB2 encoding connexin-26 cause the ectodermal dysplasia keratitis-ichthyosis- deafness syndrome. Am J Hum Genet 2002, 70:1341-1348.
52. Lamartine J, Essenfelder GM, Kibar Z, et al.: Mutations in GJB6 cause hidrotic ectodermal dysplasia. Nat Genet 2000, 26:142-144.
53. Essenfelder GJ, Bruzzone R, Lamartine J, et al.: Connexin30 mutations responsible for hidrotic ectodermal dysplasia cause abnormal hemichannel activity. Hum Mol Genet 2004, 13:1703-1714. Connexin 30 mutations are shown to affect extracellular ATP levels, presumably altering keratinocyte differentiation and proliferation.
54. Common JE, Di Becker DWL, Leigh IM, et al.: Functional studies of human skin disease- and deafness-associated connexin 20 mutations. Biochem Biophys Res Commun 2003, 298:651-656.
55. Paznekas WA, Boyadjiev SA, Shapiro RE, et al.: Connexin 43 (GJA1) mutations cause the pleiotropic phenotype of oculodentodigital dysplasia. Am J Hum Genet 2003, 72:408-418, This paper identifies GJA1 as the cause of oculodentodigital dysplasia and also provides a comprehensive review of the clinical features of the disorder.
56. Richardson R, Donnani D, Meire F, et al.: Expression of Gja1 correlates with the phenotype observed in oculodentodigital syndrome/type III syndactyly. J Med Genet 2004, 41:60-67. This paper studies the temporospatial expression profile of the murine Gja1 gene and reports nine different missense mutations in ODDD or type III syndactyly patients, seven of which are novel.
57. Pizzuti A, Flex E, Mingarelli R, et al.: A homozygous GJA1 gene mutation causes a Hallermann-Streiff/ODDD spectrum phenotype. Human Mutation 2004; Mutation in Brief #691 online.
58. Britz-Cunningham SH, Shah MM, Zuppan CW, et al.: Mutations of the connexin 43 gap-junction gene in patients with heart malformations and defects of laterality. N Engl J Med 1995, 332:1323-1329.
59. Puel A, Picard C, Cheng-lung K, et al.: Inherited disorders of NF-κB-mediated immunity in man. Curr Opin Immunol 2004, 16:34-41. This is an outstanding overview of this complex signal transduction system as it relates to clinical disease.
60. Orange JS, Geha RS: Finding NEMO: genetic disorders of NF-κB activation. J Clin Invest 2003, 112:983-985. This is a comprehensive overview of human diseases caused by various defects in the NF-κB pathway, an important regulator of cellular transcription.
61. Chen Y, Molloy SS, Thomas L: Mutations within a furin consensus sequence block proteolytic release of ectodysplasin-A and cause X-linked hypohidrotic ectodermal dysplasia. Proc Natl Acad Sci USA 2001, 98:7218-7223.
62. Yan M, Wang LC, Hymowitz SG, et al.: Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science 2000, 290:523-527.
63. Smahi A, Courtois G, Vabres P, et al.: Genomic rearrangement in NEMO impairs NF-kappaB activation and is a cause of incontinentia pigmenti. The International Incontinentia Pigmenti (IP) Consortium. Nature 2000, 405:466-472.
64. Doffinger RA, Smahi A, Bessia C, et al.: X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling. Nat Genet 2001, 27:277-285.
65. Fusco F, Bardaro T, Fimiani G, et al.: Molecular analysis of the genetic defect in a large cohort of IP patients and identification of novel NEMO mutations interfering with NF-κB activation. Hum Mol Genet 2004, 13:1763-1773. This large study of the mutation spectrum and phenotypes in IP corroborates the importance of X-inactivation patterns as well as the specific mutation in determining the severity of the IP phenotype.
66. Jain A, Ma CA, Liu S, et al.: Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia. Nat Immunol 2001, 2:223-228.
67. Orange JS, Brodeur SR, Jain A, et al.: Deficient natural killer cell cytotoxicity in patients with IKK-γ/NEMO mutations. J Clin Invest 2002, 109:1501-1509.
68. Orange JS, Jain A, Ballas ZK, et al.: The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. J Allergy Clin Immunol 2004, 113:725-733. This is an excellent review of the immunologic phenotype in EDA-ID syndrome caused by hypomorphic NEMO mutations. Molecular genotype: phenotype correlations are proposed.
69. Courtois G, Smahi A, Reichenbach J, et al.: A hypermorphic IκBα is associated with autosomal dominant anhidrotic ectodermal dysplasia and T-cell immunodeficiency. J Clin Invest 2003, 112:1108-1115.
70. Picard C, Puel A, Bonnet M, et al.: Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003, 299:2076-2079.
71. Jonkman MF, Castellanos Nuijts M, van Essen AJ: Natural repair mechanisms in correcting pathogenic mutations in inherited skin disorders. Exp Dermatol 2003, 28:625-631.
72. Smith FJD, Morley SM, McLean WHI: Novel mechanism of revertant mosaicism in Dowling-Meara epidermolysis bullosa simplex. J Invest Dermatol 2004, 122:73-77.
73. Nishikomori R, Akutagawa H, Maruyama K, et al.: X-linked ectodermal dysplasia and immunodeficiency caused by reversion mosaicism of NEMO reveals a critical role for NEMO in human T-cell development and/or survival. Blood 2004, 103:4565-4572. This article describes a phenotypically unique patient in whom revertant mosaicism of a NEMO mutation was detected. Clinical immunologic evaluations are correlated with the molecular biology, providing important implications for the role of NEMO in T cell maturation and survival. This is an excellent overview of revertant mosaicism and its possibilities for therapy in the genodermatoses.
74. Taubes G: Gene therapy. The strange case of chimeraplasty. Science 2002, 298:2116-2120.
75. Kole R, Sazani P: Antisense effects in the cell nucleus: modification of splicing. Curr Opin Mol Ther 2001, 3:229-234.